Bafetinib: Preliminary Phase II data

Preliminary data from the ongoing, U.S. Phase II ENABLE trial in 11 evaluable patients with relapsed or refractory B cell CLL who failed previous therapy showed that twice-daily 240 mg oral bafetinib ...